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ABSTRACT
Attenuated measles virus (MV) is currently being evaluated as an oncolytic 
virus in clinical trials and could represent a new therapeutic approach for malignant 
pleural mesothelioma (MPM). Herein, we screened the sensitivity to MV infection 
and replication of twenty-two human MPM cell lines and some healthy primary cells. 
We show that MV replicates in fifteen of the twenty-two MPM cell lines. Despite 
overexpression of CD46 by a majority of MPM cell lines compared to healthy cells, we 
found that the sensitivity to MV replication did not correlate with this overexpression. 
We then evaluated the antiviral type I interferon (IFN) responses of MPM cell lines 
and healthy cells. We found that healthy cells and the seven insensitive MPM cell 
lines developed a type I IFN response in presence of the virus, thereby inhibiting 
replication. In contrast, eleven of the fifteen sensitive MPM cell lines were unable 
to develop a complete type I IFN response in presence of MV. Finally, we show that 
addition of type I IFN onto MV sensitive tumor cell lines inhibits replication. These 
results demonstrate that defects in type I IFN response are frequent in MPM and that 
MV takes advantage of these defects to exert oncolytic activity.
INTRODUCTION
Antitumor virotherapy using oncolytic viruses is a 
developing strategy to treat cancer [1]. Among oncolytic 
viruses, attenuated strains of measles virus (MV) have 
been shown to infect and kill a large variety of tumor cell 
lines [2, 3]. Phase I clinical trials using the Edmonston 
strain of MV have shown clinical benefits for the treatment 
of cutaneous T cell lymphoma [4], ovarian cancer [5, 6] 
and disseminated multiple myeloma [1]. The Edmonston 
MV is also currently being evaluated in on-going phase I 
clinical trials for the treatment of squamous cell carcinoma 
of the head and the neck, glioma and mesothelioma by the 
group of Stephen J. Russell at the Mayo Clinic [1]. 
Schwarz and Edmonston attenuated strains of MV 
use the CD46 molecule as the major receptor to infect 
human cells, unlike the pathogenic strains that mainly use 
the CD150 molecule [7-9]. The membrane cofactor protein 
CD46 is ubiquitously expressed at a low level by all 
nucleated cells and blocks the complement cascade at the 
C3 activation stage [10]. CD46 is often overexpressed on 
tumor cells of many cancer types to escape complement-
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mediated cytotoxicity [11, 12]. This expression at high 
density confers to attenuated MV a natural tropism for 
tumor cells. In fact, above a certain threshold of CD46 
expression, the killing and syncitia formation mediated 
by MV infection increase dramatically [7]. Healthy cells 
that express a low level of CD46 are not infected [13]. 
Recently, nectin-4 has been described as a receptor for 
attenuated and wild-type MV, but its implication in the 
oncolytic activity of MV is still to be determined [14, 15]. 
The overexpression of CD46 is probably not 
the only factor that conditions the ability of MV to 
preferentially replicate in and kill tumor cells. In fact, 
there is now evidence that host-cell translational activity 
upon viral replication [16] and defects in the capacity 
of tumor cells to develop an antiviral innate immune 
response [17, 18] participate in MV oncolytic activity. 
All nucleated cells are equipped with intracytoplasmic 
sensors that are able to detect viral infection [19]. In the 
case of paramyxoviruses, helicases such as RIG-I and 
MDA5 detect viral RNA and induce the secretion of type 
I IFN, mainly IFN-β in non-immune cells that protect 
infected and neighboring cells from viral replication. 
Indeed, exposure to type I IFN induces in cells expressing 
the IFN-α/β receptors IFNAR1/IFNAR2 the expression 
of hundreds of IFN-sensitive genes (ISG) that exert anti-
viral activity [19]. Among these, the IFN-induced GTP-
binding protein Mx1 is able to inhibit the early steps of 
viral replication by interfering with the formation of the 
ribonucleoproteic complex [20].
 We have previously shown that the Schwarz 
attenuated strain of MV induces immunogenic cell death 
of malignant pleural mesothelioma (MPM) cells [21, 22]. 
In this study, we screened the sensitivity to MV infection 
and replication of twenty-two MPM cell lines established 
in our laboratory [23], and four different types of primary 
healthy cells. We found that fifteen MPM cell lines were 
sensitive to MV replication. We then measured the cell 
surface expression of CD46, nectin-4 and CD150, the 
three known MV receptors. We found that CD46 was often 
overexpressed by MPM cell lines compared with healthy 
primary cells and was used as an entry receptor. However, 
we failed to observe a correlation between the level of 
CD46 expression and the sensitivity of MPM tumor cell 
lines to MV replication. We then analyzed the capacity of 
the different MPM cell lines to develop a type I and type 
III IFN response after exposure to MV. We found that their 
sensitivity to MV replication was strongly related to their 
type I IFN response.
RESULTS
Sensitivity of MPM and healthy primary cells to 
MV infection
To determine the sensitivity of a large number of 
MPM cell lines to MV infection and replication, we set 
up an assay using a recombinant MV encoding the cherry 
fluorescent protein (MV-ch). By measuring fluorescence at 
610 nm, we followed daily MV-ch replication in twenty-
two MPM cell lines exposed to different multiplicities 
of viral infection (MOI) (Figure 1). Simultaneously, we 
quantified cell viability using the UptiBlueTM assay that is 
based on their metabolic activity. We also filmed by time-
lapse microscopy some of the MPM cell lines exposed to 
MV encoding the enhanced green fluorescent protein (MV-
eGFP) at an MOI = 1 (Videos 1-9). We observed no or low 
replication of MV in seven tumor cell lines. For five of 
these, no MV replication was observed: Meso4 (Video 1), 
Meso45, Meso52 (Video 2), Meso61 and Meso173, but 
their viability decreased at the highest MOI. For the other 
two tumor cell lines, Meso95 and Meso150 (Video 3), MV 
replicated in a few cells, which then induced apoptosis of 
the neighboring non-infected cells. 
In the fifteen other MPM cell lines we observed 
a strong replication of MV that led to cell death, with 
kinetics depending on the cell lines. MPM cell lines such 
as Meso31, Meso35, Meso152 and Meso225 underwent 
cell death quite fast after infection (Videos 4, 5, 6, 7), 
whereas for other sensitive cell lines, such as Meso11 and 
Meso163, cell death was slower (Videos 8, 9). This delay 
allows these latter cell lines to accumulate fluorescence 
resulting from viral replication. We also observed that 
infection was usually accompanied by the formation 
of syncytia (Videos 4, 6, 7, 8), but not in all tumor cell 
lines (Videos 5, 9). Green fluorescence measured in the 
videos (Supplemental figure 1) was very similar to the 
results obtained with cherry fluorescence measured using 
MV-ch (Figure 1). We observed no replication or very 
limited replication in Meso4, 52 and 150, a replication 
that stopped around day 3 and day 4 for Meso31, 35, 
152 and 225, and a replication that continued after day 5 
for Meso11 and 163. Altogether, these results show that 
approximately 70% of MPM tumor cell lines are sensitive 
to the replication and oncolytic activity of Schwarz MV.
Using the same techniques, we also measured 
the sensitivity to MV infection of four different human 
primary healthy cell types: peritoneal mesothelial cells 
(MES-F), bronchial epithelial cells (CEB), pulmonary 
endothelial cells (HMVEC-L) and lung fibroblasts (CCD-
19Lu) (Figure 2). We observed no infection of CEB 
(Supplemental video 10) and a very limited infection with 
no syncytia formation for MES-F (Supplemental video 
11), HMVEC-L, and CCD-19Lu cells. The viability of 
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Figure 1: A majority of MPM tumor cell lines are sensitive to MV replication and oncolytic activity. MPM cell lines were 
infected with MV-ch or MV at different MOI: 0.1 (circles), 1 (squares) and 10 (triangles). MV-ch and MV were used for the MV replication 
assay and the cell viability assay, respectively. The fluorescence values correspond to the ratio between the fluorescence measured in 
infected tumor cells and non-infected cells. Cell viability is expressed as a percentage compared to non-infected cells. Results are expressed 
as the mean ±SEM of three independent experiments. 
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these primary cells decreased, especially at the highest 
MOI.
Expression of CD46, CD150 and nectin-4 by 
MPM and healthy primary cells
We measured the expression of known MV receptors 
(CD46, CD150 and nectin-4) on the surface of MPM 
and healthy primary cells. The majority of MPM cells 
expressed higher levels of CD46 than healthy primary 
cells (Figure 3A-3B). However, no statistical difference 
was observed between MPM cells sensitive or not to MV 
infection (Figure 3B). We did not detect any expression 
of CD150 or nectin-4 (Supplemental figure 2), which are 
receptors for the pathogenic as well as vaccine MV strains 
[14, 15, 24]. Altogether these data show that a majority 
of tumor MPM cell lines overexpress CD46 as the only 
known MV receptor and that sensitivity of these cells to 
MV infection is not related to CD46 expression.
MV uses CD46 to infect MPM tumor cells
To determine whether CD46 plays a role in MPM 
cell infection, we exposed eight MPM cell lines to MV-
ch in the presence of anti-CD46 mAb or isotype control 
mAb (Figure 3C). On Meso4, which is not sensitive to MV 
infection, the anti-CD46 mAb had no effect on replication, 
but slightly increased cell viability. On the seven other 
MV-sensitive cell lines, the anti-CD46 mAb significantly 
delayed MV replication and cell death. These delays were 
similar to the shifts observed between infection at MOI 
= 1 and 0.1 (Figure 1A), suggesting that the anti-CD46 
mAb inhibited approximately 90% of the infection. This 
demonstrates that CD46 is required for MV infection of 
MPM tumor cells.
IFN type I response prevents MV replication in 
MPM tumor cells and healthy primary cells
Since the sensitivity of MPM tumor cell lines to MV 
replication did not correlate with the CD46 expression 
level (Figure 3B), we sought to identify other factors that 
condition sensitivity to MV replication. We investigated 
the activation of antiviral type I and III IFN response by 
tumor cell lines and healthy primary cells exposed for 72 
hours to MV by analyzing the expression of five specific 
genes by RT-qPCR (Figure 4).
We first analyzed the expression of two helicase 
genes: the DDX58 gene that encodes the retinoic acid-
inducible gene-1 protein (RIG-I) and the IFIH1 gene that 
encodes melanoma differentiation-associated protein 5 
(MDA5). These two proteins are intracytoplasmic sensors 
of viral ssRNA and dsRNA, able to induce type I IFN 
response against MV [25]. We observed that following 
MV exposure, the expression of both genes was increased 
in all tumor cell lines and healthy primary cells, thus 
indicating that MV was detected by all these cells (Figure 
4). 
We then looked at the expression of two type I IFN 
genes: IFNA1 and IFNB1 that encode IFN-α and IFN-β 
,respectively (Figure 4). Constitutive expression of IFNA1 
was observed in the absence of MV in all healthy cells 
and in all insensitive tumor cell lines, with the exception 
of Meso173. IFNA1 expression was increased in all these 
Figure 2: Healthy cells are not sensitive to MV replication. 4 types of healthy cells (mesothelial cells MES-F, bronchial epithelial 
cells CEB, pulmonary endothelial cells HMVEC-L and pulmonary fibroblasts CCD-19Lu) were infected with MV-ch or MV at different 
MOI: 0.1 (circles), 1 (squares) and 10 (triangles). MV-ch and MV were used for the MV replication assay and the cell viability assay, 
respectively. The fluorescence values correspond to the ratio between the fluorescence measured in infected tumor cells and non-infected 
cells. The cell viability is expressed as a percentage compared to non-infected cells. Results are expressed as the mean ±SEM of three 
independent experiments. 
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cell lines in the presence of the virus, with the exception 
of CEB. In the fifteen sensitive tumor cell lines, a weak 
constitutive expression of IFNA1 in the absence of the 
virus was found in six tumor cell lines (Meso35, 36, 37, 
56, 34 and 122) and was increased in the presence of MV 
in four of these (Meso35, 36, 34 and 122). In the nine 
other sensitive tumor cell lines, we never detected IFNA1 
expression, either in the presence or absence of MV. 
Regarding IFNB1, a weak constitutive expression in the 
absence of the virus was detected only in the insensitive 
Figure 3: Absence of correlation between CD46 surface expression and MPM sensitivity to MV replication. (A) 
Expression of CD46 is measured on the cell surface by flow cytometry. Results are expressed as RMFI ± SEM of three independent 
experiments. (B) Scatter plot representation of the CD46 expression on healthy and tumor cells surfaces. Each point represents the mean 
of RMFI obtained in three independent experiments. * p < 0.05, Mann-Whitney test. (C) MV replication and cell viability were assessed 
after MV-ch or MV infection, respectively (MOI = 1) in the presence or absence of an anti-CD46 blocking mAb. An isotype was used 
as a control. The fluorescence values correspond to the ratio between the fluorescence measured in infected tumor cells and non-infected 
cells. The cell viability is expressed as a percentage compared to non-infected cells. Results are expressed as the mean ±SEM of three 
independent experiments. 
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Figure 4: The sensitivity to MV infection depends on defects of the antiviral type I IFN response. The expression of five 
genes implicated in the antiviral type I IFN response was analyzed by RT-qPCR 72 hours after MV infection of tumor and healthy cells 
(MOI = 1). The expression is expressed as relative expression compared to RPLPO gene expression. Non-infected cells (NI) are in light 
gray and infected cells (MV) are in dark gray. The DDX58 and IFIH1 genes code for RIG-I and MDA5 proteins, respectively. The IFNA1 
gene codes for IFN-α, IFNB1 for IFN-β, and Mx1 for Mx1 protein. For each gene, a histogram shows the expression by each cell line, and a 
scatter plot shows the expression by groups (healthy cells, tumor cells with no MV replication, tumor cells with MV replication). Results are 
expressed as the mean ±SEM of three independent experiments. * p < 0.05; **p < 0.01; ***p < 0.001, one-way ANOVA (Kruskal-Wallis). 
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Meso52 cell line (Figure 4). In the presence of MV, we 
measured a significant induction of IFNB1 expression in 
all insensitive tumor cells lines and in all healthy cells, 
even in CEB in which IFNB1 expression was increased 
20-fold. In contrast, seven out of the fifteen sensitive 
tumor cell lines expressed IFNB1 in response to the virus 
(Meso35, 36, 37, 56, 152, 34 and 122), whereas the eight 
other sensitive tumor cell lines did not. We also measured 
the expression of the IFNL1 gene that encodes the type III 
IFN, IFN-λ1 (Supplemental Figure 3). In contrast to type 
I IFN, all tumor cell lines were able to express this gene 
in the presence of the virus with no significant differences 
whether MV-sensitive or not.
Finally, we measured the expression of the MX1 
gene that encodes the interferon-induced GTP-binding 
protein Mx1. The MX1 gene is an ISG that is expressed 
following signaling from the type I IFN receptor, IFNAR1/
IFNAR2. Among healthy primary cells, we found a 
weak constitutive expression of MX1 only in HMVEC-L 
(Figure 4E). In the presence of MV, a strong increase 
of MX1 expression was induced in all healthy cells. 
Similarly, in MV-insensitive MPM cell lines, the weak 
constitutive expression of MX1 was highly increased after 
MV addition. Conversely, among the fifteen MV-sensitive 
MPM cell lines, we found no constitutive expression of 
MX1 in eleven, a weak constitutive expression in three 
(Meso36, 37, 122) and a strong constitutive expression 
only for one (Meso34). In the presence of MV, we 
observed a significant increase of MX1 expression only 
for Meso36. The MX1 expression did not change for all 
the other sensitive cell lines. 
These results indicate that cells that are able to 
develop a complete type I IFN response, whether they 
are healthy primary or tumor cells, are not sensitive to 
MV infection. On the contrary, tumor cell lines that are 
unable to develop a type I IFN response are sensitive to 
MV infection, with the four exceptions, Meso36, 37, 34 
and 122, which express IFNA1, IFNB1 and MX1 and are 
sensitive to MV replication. These results also signify that 
the capacity to achieve a complete type I IFN response is 
defective in numerous MPM cell lines.
We then sought to confirm these results by 
measuring IFN-α and IFN-β secretion by ELISA in the 
culture supernatants (Figure 5). Regarding IFN-α,we did 
not detect significant secretion in the supernatants of tumor 
cell lines and healthy primary cell cultures in the absence 
of MV, except for Meso52 (Figure 5). This suggests 
that the IFN-α mRNA observed by RT-qPCR in several 
tumor cell lines in the absence of the virus was either not 
translated into proteins or resulted in levels undetectable 
by ELISA. In the presence of MV, IFN-α was significantly 
secreted by all insensitive cell lines and by two out of three 
healthy primary cell cultures, whereas only four out of the 
fifteen sensitive tumor cell lines (Meso36, 37, 34 and 122) 
Figure 5: Secretion of the type I IFN, IFN-α and IFN-β, after MV infection. IFN-α and IFN-β secretion was measured by 
ELISA, 72 hours after MV infection of tumor and healthy cells (MOI = 1). Non-infected cells (NI) are in light gray and infected cells 
(MV) are in dark gray. For each IFN, a histogram shows the expression by each cell line, and a scatter plot shows the expression by groups 
(healthy cells, tumor cells with no MV replication, tumor cells with MV replication). Results are expressed as the mean ±SEM of three 
independent experiments. 
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secreted IFN-α. Regarding IFN-β, the results obtained by 
RT-qPCR were confirmed with the observation that this 
cytokine was secreted by all insensitive cell lines and 
healthy primary cells cultures, and by only six out of the 
fifteen sensitive cell lines (Meso35, 36, 37, 56, 34 and 
122) (Figure 5). Interestingly, the four sensitive cell lines 
secreting IFN-α in the presence of the virus also secreted 
IFN-β.
We also measured the cytoplasmic expression of 
Mx1 protein by flow cytometry in tumor cell lines and 
healthy primary cells (Figure 6). We found high levels of 
Mx1 in the cytoplasm of healthy primary cells only when 
they were exposed to MV. In all insensitive tumor cell 
lines, we found cytoplasmic Mx1 in non-infected cells that 
was increased in the presence of MV, except for Meso52 
where Mx1 was already present in equally high amounts 
in absence of the virus. For the fifteen tumor cell lines 
sensitive to MV replication, cytoplasmic Mx1 was not 
detected in the absence of MV except for four cell lines 
(Meso34, 36, 37 and 122). In the presence of MV, six out 
of the fifteen sensitive cell lines did not express Mx1 in 
their cytoplasm (Meso31, 47, 76, 225, 13 and 11), five 
expressed low levels in a fraction of the cells (Meso35, 
56, 96, 152, and 163) and the last three expressed high 
levels of Mx1 in 100% of the cells (Meso34, 36, 37 and 
122) similarly to what was observed in insensitive tumor 
cell lines. 
Overall, these results show that tumor cells that 
constitutively express Mx1 are not sensitive to MV 
replication, with the exception of Meso34, 36, 37 and 122. 
They also demonstrate that the cells that fail to develop a 
complete type I IFN response, illustrated by the absence 
of IFN-α, IFN-β and Mx1 expression, are sensitive to MV 
replication with the same exceptions: Meso34, 36, 37 and 
122.
IFN-α and IFN-β inhibit MV replication in MPM 
cell lines sensitive to MV replication
In the last set of experiments we tested the effect 
of type I IFN (IFN-α and IFN-β) on MV replication in 
sensitive tumor cell lines. We first measured the expression 
of IFNAR1 and IFNAR2 in all MPM cells lines. A low 
expression was found on the surface of all tumor cell lines 
(data not shown). We then exposed the fifteen MPM cell 
lines sensitive to MV to increasing amounts of IFN-α and 
IFN-β and measured MV replication using MV-ch (Figure 
7). MV replication was reduced in a dose-dependent 
manner in all tumor cell lines. Interestingly, the inhibition 
was lower in three out of the four MPM cell lines that 
express IFN-α, IFN-β and Mx1 constitutively (Meso34, 
36 and 37), whereas the inhibition was more profound in 
tumor cell lines that did not develop a type I IFN response 
in the presence of the virus, such as Meso31, 47, 76, 225 
and 11. In addition, exposure to IFN-α and IFN-β induced 
a strong expression of Mx1 in all of these fifteen sensitive 
tumor cell lines (data not shown). These results show that 
the majority of MPM cell lines that are sensitive to MV 
replication would not be able to replicate the virus if they 
were able to produce their own type I IFN in response to 
the virus.
DISCUSSION
In this study, we measured the sensitivity of a large 
panel of human MPM tumor cell lines and of different 
types of healthy cells to the oncolytic activity of the 
Schwarz vaccine strain of MV. We found that fifteen out 
of twenty-two MPM tumor cell lines are sensitive to MV 
replication and cytopathic effect, whereas replication 
was limited or absent in the four types of healthy cells 
(fibroblasts, mesothelial, bronchial and endothelial cells) 
as well as in the seven remaining MPM tumor cell lines. 
Figure 6: Sensitivity to MV replication correlates with the absence of expression of the antiviral protein Mx1. 
Intracytoplasmic Mx1 staining was performed on non-infected (NI) or on MV-infected tumor cells (MOI = 1, 72h) and fluorescence was 
analyzed by flow cytometry. The histogram represents the expression of Mx1 (RMFI) by each cell line (NI is in light gray and MV in 
dark gray), and the scatter plot shows Mx1 expression by groups (healthy cells, tumor cells with no MV replication, tumor cells with MV 
replication). Results are expressed as the mean ±SEM of three independent experiments. *p < 0.05, One-way ANOVA (Kruskal-Wallis). 
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Our data also show that the sensitivity of tumor cell lines 
is not correlated to overexpression of the MV cell receptor 
CD46, contrary to what has been described in the literature 
[3, 7]. Nevertheless, the virus needs CD46 to enter the 
cells. In a search for factors that affect the sensitivity of 
MPM tumor cells to MV oncolytic activity, we studied 
the innate antiviral type I and III IFN immune response 
of these cells. Our results suggest that MV enters into 
all tumor cell lines and healthy cells, since we observed 
the upregulation of genes encoding the cytoplasmic viral 
sensors RIG-I and MDA5 in the presence of the virus. 
However, we observed type I IFN production (IFN-α and 
-β) mainly by insensitive tumor cell lines and healthy 
cells exposed to MV. More strikingly, when we analyzed 
the expression of the ISG Mx1, we found this protein 
in the cytoplasm of all insensitive tumor cell lines and 
healthy cells exposed to MV. In contrast, eleven out of 
fifteen sensitive tumor cell lines were unable to express a 
high level of Mx1 in response to MV. Overall, this study 
suggests that about 70% of MPM patients are potentially 
sensitive to MV oncolytic activity and that this activity 
depends on defects in the intracellular innate antiviral 
response in MPM tumor cells rather than on CD46 
overexpression on the cell surface.
We observed that exposure of insensitive tumor cell 
lines or healthy cells to high titers of MV (MOI = 10) 
results in viability loss for the majority of them. This is 
likely due to the induction of the innate antiviral immune 
response that is known to affect viability, notably by 
limiting host translational activity or by inducing apoptosis 
[19]. This is particularly true for the MPM tumor cell lines 
Meso95 and Meso150. For these cells, we observed that 
infection of a limited number of cells induces apoptosis 
of neighboring non-infected cells (Supplemental video 
2). Apoptosis of non-infected cells was also observed at 
the lowest MOI, suggesting that a few infected cells are 
sufficient to induce apoptosis of neighboring cells. We 
classified Meso95 and Meso150 as tumor cell lines that 
are insensitive to MV replication. However, they could be 
considered as sensitive to the oncolytic activity of MV, 
even if MV replication is limited to a few cells. Overall, 
these results show that seventeen out of the twenty-two 
studied MPM tumor cell lines (77%) are sensitive to the 
oncolytic activity of MV. Furthermore, MV still has an 
effect on insensitive tumor cell lines by inducing a strong 
type I IFN response that could be beneficial for the patient 
by increasing tumor immunogenicity [26-28]. 
Two other groups recently studied the implication 
of the intracellular antiviral response on the sensitivity 
of tumor cell lines to MV oncolytic activity [16-18]. 
Berchtold and collaborators studied the sensitivity of 
eight human sarcoma tumor cell lines to the Schwarz 
strain of MV [18]. They found that five out of eight tumor 
cell lines were sensitive, whereas the remaining three 
were not. They then observed that the three insensitive 
cell lines express on their surface a lower level of CD46 
molecules compared to the five sensitive cell lines, a result 
compatible with the accepted view that the oncolytic 
activity of MV depends on overexpression of CD46 by 
tumor cells [3, 7]. They also analyzed type I IFN response 
in tumor cells exposed to MV. When they analyzed the 
completion of this response by measuring expression of 
the ISG IFIT1, they found that it was expressed in the 
three insensitive cell lines and only in one out of the five 
sensitive cell lines. This last result matches our results 
that were obtained on a larger series of tumor cell lines 
Figure 7: Type I IFN inhibit MV replication in the majority of MV-sensitive tumor cell lines. MPM cell lines were infected 
with MV-ch (MOI = 1) in the presence of different amounts of IFN I (IFN-α and IFN-β) for MV replication assay. The fluorescence values 
correspond to the ratio between the fluorescence measured in infected tumor cells in the presence or absence of type I IFN and the non-
infected cells. Data represent the mean ±SEM of three independent experiments.
Oncotarget10www.impactjournals.com/oncotarget
and also on some healthy primary cells. The same group 
confirmed this result in an additional study where they 
analyzed type I IFN response in five MV-insensitive tumor 
cell lines compared to one sensitive tumor cell line [17]. 
They found that four out of the five insensitive tumor cell 
lines expressed IFIT1 in the presence of the virus, whereas 
the remaining insensitive cell line and the sensitive one 
did not develop a type I IFN response. The MV receptor 
level was not measured in this study. Finally, Patel and 
collaborators studied the sensitivity of seven human lung 
adenocarcinoma cell lines and two types of healthy cells to 
the Edmonston strain of MV [16]. They also analyzed PKR 
antiviral activity, whose expression is dependent on the 
type I IFN response, in two sensitive and one insensitive 
tumor cell line. Their results suggest that the PKR antiviral 
activity plays a role in the limited infection of the resistant 
tumor cell line by limiting the host transcriptional activity. 
Overall, our study performed on twenty-two MPM cell 
lines and four types of primary cells confirms and extends 
the previous conclusions obtained on a limited number 
of tumor cell lines that the type I IFN response in tumor 
cells affects their sensitivity to MV oncolytic activity. 
Furthermore, we clearly show that type I IFN defects play 
a greater role than CD46 overexpression.
We observed that some tumor cell lines that appear 
to develop a type I IFN response are nevertheless sensitive 
to MV oncolytic activity, as also observed in other studies 
[16-18]. This observation could be explained by the 
presence of two cellular subpopulations in these tumor 
cell lines: one sensitive subpopulation unable to express 
ISG in the presence of the virus, and one insensitive 
subpopulation competent in type I IFN response. However, 
we ruled out this hypothesis since we observed only one 
Mx1-positive population in these tumor cell lines in the 
presence of MV. This suggests that in sensitive tumor 
cell lines that produce type I IFN and express Mx1 in 
response to MV, other ISG involved in the inhibition of 
MV replication are missing. Indeed, while hundreds of 
ISG have been identified, we only studied Mx1 whose 
role in MV replication is not well characterized, especially 
with attenuated strains [29, 30]. Furthermore, this activity 
is likely to be cell-type dependent. It is thus possible that 
Mx1 antiviral activity acts in combination with other ISG 
that are not expressed in the four sensitive tumor cell lines 
that produce type I IFN and express Mx1 in response 
to MV, whereas these required ISG are expressed in 
the seven insensitive tumor cell lines, thereby blocking 
MV replication. In support of this hypothesis, it was 
demonstrated in a study that analyzed expression of 380 
ISG in response to a panel of viruses that most ISG do not 
inhibit viral replication when expressed individually, and 
that antiviral activity is observed when ISG are expressed 
in combination [31, 32]. 
We thought to confirm these results in vivo with 
experiments on human MPM tumors engrafted in 
immunodeficient mice as we previously did for colon and 
lung adenocarcinoma [33]. However, these models are 
very different from what may happen in immunocompetent 
patients. Indeed, in these models, healthy mouse cells do 
not express receptors for MV and would not produce type 
I IFN. In addition, there is no immune system in these 
mice to respond to type I IFN produced by insensitive 
tumor cells. Thus, an immunocompetent animal model for 
mesothelioma needs to be developed to extend this study 
in vivo.
MV is currently being evaluated in clinical trials for 
the treatment of different types of cancers [1] and the first 
published results are promising [4-6, 34]. In our study, 
we define more precisely the mechanisms that dictate the 
sensitivity of MPM tumor cells to MV. These mechanisms 
should be taken into consideration to analyze the clinical 
outcome of MV-based virotherapy. It would be probably 
informative to know the type I IFN response capability of 
tumor cells from responding patients to better understand 
the efficacy of this therapeutic strategy.
MATERIALS AND METHODS
Cell culture
Human MPM cell lines (from Meso4 to Meso225) 
were established in our laboratory from pleural effusions 
collected by thoracocentesis, and genetically characterized 
[23]. All patients gave their informed consent. All cell lines 
were maintained in RPMI-1640 medium supplemented 
with 10% heat-inactivated fetal calf serum, 100U/mL 
penicillin, 100µg/mL streptomycin and 2mM L-glutamine 
(all reagents from Gibco-Invitrogen) and cultured at 37°C 
in a 5% CO2 atmosphere.
Normal peritoneal mesothelial cells MES-F were 
purchased from Tebu-bio, pulmonary fibroblasts CCD-
19Lu from the ATCC-LGC Standards, and pulmonary 
endothelial cells HMVEC-L from Lonza. These cells 
were cultured in their specific media according to the 
manufacturers’ recommendations. The bronchial epithelial 
cells were obtained and cultured as previously described 
[35]. Cells were routinely checked for Mycoplasma 
contamination using the PlasmoTestTM from InvivoGen.
MV infection
Live-attenuated Schwarz vaccine strain of measles 
virus (MV), MV recombinant for the enhanced green 
fluorescent protein (MV-eGFP) and MV recombinant for 
the cherry protein (MV-ch) were produced and purified 
as previously described [36]. Infection of cells with the 
different measles virus vaccinal strains lasted 2 hours at 
37°C. Viral inoculum was then replaced by fresh culture 
medium, unless otherwise indicated.
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MV replication assay
A day before infection, cells were seeded in 96-well 
plates, at a density of 5,000 cells/well for the MPM cell 
lines, and at the recommended density for each healthy 
cell type. Different multiplicities of infection (MOI) 
were used for infection with MV-ch (0.1, 1 and 10). 
Fluorescence at 610nm was analyzed every day during 
10 days using a ChemiDoc™ MP imaging system (Bio-
Rad). Quantification was performed using Image Lab 
4.1 Software (Bio-Rad) with the relative fluorescence 
corresponding to the ratio between the fluorescence 
measured in infected cells and the non-infected cells. The 
medium was replaced every 3 days to match the conditions 
of the cell viability assay. For the CD46 blocking assay, we 
used a CD46-specific mAb (clone M177, Hycult Biotech) 
or a mouse IgG1 isotype as a control (clone MOPC-21, 
Biolegend) at a final concentration of 10µg/mL. These 
antibodies were added 30 minutes before adding the MV-
ch at an MOI = 1. To test the inhibition of MV replication 
with type I IFN, we added rhIFN-alpha-2a and rhIFN-
beta-1a (ImmunoTools) at concentrations ranging from 
10IU/mL to 10,000IU/mL, 4 hours before the infection 
with MV-ch at MOI = 1, and the viral inoculum was not 
replaced for this assay.
Cell viability assay
Cells were seeded in 96-well plates and infected 
with MV as described in the previous paragraph. Cell 
viability was measured using Uptiblue reagent (Interchim), 
an oxidation-reduction sensor that indicates cell metabolic 
activity. At days 3, 6 and 9 after the infection, the Uptiblue 
reagent was added (5%, v/v) into the culture medium 
for 2 hours at 37°C. Fluorescence was then measured at 
590nm using a ChemiDoc™ MP imaging system (Bio-
Rad). Quantification was performed using Image Lab 4.1 
Software (Bio-Rad) and the viability was expressed as a 
percentage compared to non-infected cell viability. Culture 
medium containing Uptiblue was then replaced by fresh 
medium to continue the kinetic experiment. 
Video microscopy
A day before infection, cells were seeded in 24-
well plates, at a density of 105cells/well for the MPM cell 
lines, and at the recommended density for healthy cells. 
Cells were infected with MV-eGFP (MOI = 1). The time-
lapse video microscopy was performed using a Leica 
DMI6000B microscope with a 10x objective. Images were 
acquired every 15 or 30 minutes for 3 to 4.5 days. We used 
MetaMorph® Microscopy Automation & Image Analysis 
Software (version 7.8) and Fiji Software for acquisition 
and analysis.
Flow cytometry
To measure CD46 expression on the cell surface, we 
stained the cells with a FITC-conjugated anti-CD46 mAb 
(clone E4.3, BD Biosciences). Fluorescence was measured 
on FACS Calibur (BD Biosciences) and analyzed using 
FlowJo software. The results are expressed as relative 
mean of fluorescence intensity (RMFI). To measure 
Mx1 in the cytoplasm 72 hours after infection with MV 
at MOI = 1, cells were fixed with PBS containing 4% 
paraformaldehyde for 10 minutes at room temperature. 
Cell washes and mAb dilutions were performed with PBS 
containing 0.1% BSA (bovine serum albumin) and 0.1% 
saponin. Unconjugated anti-Mx1 mAb (clone M143, Dr. 
Georg Kochs, University Medical Center Freiburg) and, 
as a control, an unconjugated mouse IgG2a isotype (clone 
MOPC-173, Biolegend) were used. A DyLightTM488-
conjugated anti-mouse IgG antibody (clone Poly4053, 
Biolegend) was used as secondary antibody. The results 
are expressed as RMFI. 
Real-time RT-qPCR
MPM cell lines and healthy cells were seeded 
in 6-well plates at a density of 0.5x106cells/well and 
infected with MV at MOI = 1. 72 hours after infection, 
total cell RNA was extracted using the Nucleospin® 
RNA II kit (Macherey-Nagel) and 0.5µg total RNA was 
reverse transcribed using MMLV reverse transcriptase 
(Invitrogen). PCR reactions were conducted using 
QuantiTect primer assays (Qiagen) and Maxima SYBR 
Green/ROX qPCR Master Mix (Fisher Scientific) 
according to the manufacturer’s instructions. Gene 
expression was analyzed in non-infected and infected 
cells using QuantiTect primers pairs for IFNA1 (coding 
for IFN-α), IFNB1 (IFN-β), IFNL1 (IFN-λ1), Mx1 (Mx1), 
DDX58 (RIG-I) and IFIH1 (MDA5). The gene expression 
was expressed as relative expression compared to the 
expression of a housekeeping gene that encodes human 
large ribosomal protein (RPLPO).
Cytokine detection
IFN-α and IFN-β production were measured by 
ELISA (MabTech and PBL Assay Science, respectively), 
according to the manufacturer’s instructions. Supernatants 
of MPM cell lines and healthy cells were collected 
72 hours after infection with MV at MOI = 1 and used 
directly for ELISA without freezing.
Statistical analysis
Statistical analysis was performed using GraphPad 
Prism 5 software (GraphPad Software Inc.) . To compare 
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two groups, a nonparametric, one-sided, unpaired Mann-
Whitney comparison test was used. For statistical analysis 
comparing more than two groups, nonparametric one-way 
ANOVA (Kruskal-Wallis test) was used, with Dunn’s post-
test. All data are presented as mean±SEM. P values less 
than 0.05 were considered to be statistically significant. *p 
< 0.05, **p < 0.01, ***p < 0.001.
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